Optimum News

MUNICH and FRANKFURT, Germany, September 18, 2018 /PRNewswire/ — Pioneering project will enable start-ups to accelerate time to market for innovative health-related products and services aescuvest and EIT Health announce … Continue reading “aescuvest and EIT Health Launch First Pan-European Equity Crowdfunding Platform for Healthcare”

LONDON, 12 September 2018: Arix Bioscience plc (“Arix”) (LSE: ARIX), a global healthcare and life science company supporting medical innovation, today announced that industry veteran Arthur Pappas has been appointed … Continue reading “ARIX Bioscience Plc Announces Board Changes, Appointment of Arthur Pappas to the Board of Directors, David U’Prichard to retire from Board”

Forendo Pharma, a clinical stage drug development company focusing on novel treatments in women’s health, today announces that it has raised an additional €4 million of funding from Vesalius Biocapital … Continue reading “Vesalius Biocapital III Partners joins Forendo Pharma Investor Syndicate”

Amsterdam, The Netherlands, August 30, 2018 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that Robbert van Heekeren is … Continue reading “Kiadis Pharma announces resignation of Robbert van Heekeren and appoints Scott A. Holmes as new Chief Financial Officer”

Novo Nordisk gains full rights to Ziylo’s early-stage glucose binding molecules in a staged acquisition with a potential deal value that could exceed 800 million US dollars The acquisition supports … Continue reading “Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins”

Ziylo’s technology platform could accelerate the development of a groundbreaking treatment for diabetes patients A new company, Carbometrics, has been set up to develop novel diagnostics and glucose monitoring BRISTOL, … Continue reading “Ziylo acquired by Novo Nordisk in deal that could exceed US$800m”

Arix interest increased to £15.3 million ($19.7 million1), becoming largest shareholder in Artios. Supporting proven management team in accelerating development of next generation DNA Damage Response (DDR) pipeline Arix Bioscience … Continue reading “Arix Bioscience Plc – Artios completes £65m Series B investment round”

Financing Round Led by New Investors Andera Partners and LSP Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing innovative treatments for cancer, today announced the completion … Continue reading “Artios Pharma Announces $84 million (£65 million) Series B Financing”

Arix Bioscience leads A$24 million (£13.4 million) financing for Pharmaxis Funding to accelerate the development of Pharmaxis’ fibrosis and anti-inflammatory programmes, as the company advances numerous candidates from its Amine … Continue reading “Arix Bioscience announces first VIPE investment”